Selective dose escalation of chemoradiotherapy for locally advanced esophageal cancer

被引:3
作者
Seung, S. K. [1 ,2 ]
Smith, J. W., II [3 ]
Ross, H. J. [1 ,2 ]
机构
[1] Earle A Chiles Res Inst, Portland, OR USA
[2] Oregon Clin, Portland, OR USA
[3] NW Canc Specialists, Portland, OR USA
关键词
amifostine; chemotherapy; esophageal neoplasms; radiotherapy;
D O I
10.1111/j.1442-2050.2008.00822.x
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
This phase II study assessed the use of concurrent continuous infusion of 5-fluorouracil and weekly carboplatin plus paclitaxel with selective radiation dose escalation for patients with localized esophageal cancer. Patients with esophageal carcinoma were staged by thoracic and abdominal computed tomography, endoscopic ultrasound, and positron emission tomography scans. Patients received a continuous infusion of 5-fluorouracil 225 mg/m(2) on days 1 to 38 and intravenous paclitaxel 45 mg/m(2) and carboplatin AUC 2 on days 1, 8, 15, 22, 29, and 36. Radiotherapy was delivered in 1.8-Gy fractions, 5 d/wk for 5.5 weeks. Six to 8 weeks after initial therapy, patients without metastatic progression but with a positive biopsy, or less than partial response received a 9-Gy boost with the same concurrent chemotherapy. Twenty-four patients were enrolled: 18 patients were enrolled initially; 6 additional patients were enrolled following a protocol amendment designed to reduce the esophagitis by adding the radioprotectant amifostine. Median follow-up was 30 months. Twenty (83%) patients had adenocarcinomas of the lower esophagus/gastroesophageal junction. Seventeen patients (81%) attained at least a partial response. Six patients received boost treatment. At 4 years, overall survival was 28%, cause-specific survival was 38%, locoregional control was 61%, and distant metastasis-free survival was 52%. Radiation delays ranged from 0 to 62 days (median, 8 d), primarily owing to esophagitis. In total, 28% of patients developed esophageal strictures requiring dilatations. There were no differences in esophageal strictures, local control, or survival with the addition of amifostine.
引用
收藏
页码:589 / 595
页数:7
相关论文
共 31 条
  • [1] [Anonymous], CANC FACTS FIG 2007
  • [2] Amifostine reduces radiochemotherapy-induced toxicities in patients with locally advanced non-small cell lung cancer
    Antonadou, D
    Petridis, A
    Synodinou, M
    Throuvalas, N
    Bolanos, N
    Veslemes, M
    Sagriotis, A
    [J]. SEMINARS IN ONCOLOGY, 2003, 30 (06) : 2 - 9
  • [3] ARAUJO CMM, 1991, CANCER, V67, P2258, DOI 10.1002/1097-0142(19910501)67:9<2258::AID-CNCR2820670908>3.0.CO
  • [4] 2-G
  • [5] Beseth BD, 2000, AM SURGEON, V66, P827
  • [6] CONTINUING CLIMB IN RATES OF ESOPHAGEAL ADENOCARCINOMA - AN UPDATE
    BLOT, WJ
    DEVESA, SS
    FRAUMENI, JF
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1993, 270 (11): : 1320 - 1320
  • [7] Chemoradiotherapy followed by surgery compared with surgery alone in squamous-cell cancer of the esophagus
    Bosset, JF
    Gignoux, M
    Triboulet, JP
    Tiret, E
    Mantion, G
    Elias, D
    Lozach, P
    Ollier, JC
    Pavy, JJ
    Mercier, M
    Sahmoud, T
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1997, 337 (03) : 161 - 167
  • [8] CARBOPLATIN DOSAGE - PROSPECTIVE EVALUATION OF A SIMPLE FORMULA BASED ON RENAL-FUNCTION
    CALVERT, AH
    NEWELL, DR
    GUMBRELL, LA
    OREILLY, S
    BURNELL, M
    BOXALL, FE
    SIDDIK, ZH
    JUDSON, IR
    GORE, ME
    WILTSHAW, E
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (11) : 1748 - 1756
  • [9] Chemoradiotherapy of locally advanced esophageal cancer - Long-term follow-up of a prospective randomized trial (RTOG 85-01)
    Cooper, JS
    Guo, MD
    Herskovic, A
    Macdonald, JS
    Martenson, JA
    Al-Sarraf, M
    Byhardt, R
    Russell, AH
    Beitler, JJ
    Spencer, S
    Asbell, SO
    Graham, MV
    Leichman, LL
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1999, 281 (17): : 1623 - 1627
  • [10] Devesa SS, 1998, CANCER, V83, P2049, DOI 10.1002/(SICI)1097-0142(19981115)83:10<2049::AID-CNCR1>3.0.CO